No abstract available
Publication types
-
Clinical Trial, Phase I
-
Multicenter Study
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / pharmacokinetics*
-
Antineoplastic Agents, Immunological / administration & dosage*
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / pharmacokinetics
-
Chemotherapy, Adjuvant
-
Dose-Response Relationship, Drug
-
Drug-Related Side Effects and Adverse Reactions / blood
-
Drug-Related Side Effects and Adverse Reactions / immunology
-
Female
-
Granulocyte-Macrophage Colony-Stimulating Factor / immunology
-
Humans
-
Leukemia, Myelomonocytic, Chronic / drug therapy*
-
Leukemia, Myelomonocytic, Chronic / metabolism
-
Leukemia, Myelomonocytic, Chronic / therapy
-
Male
-
Maximum Tolerated Dose
-
Middle Aged
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / pharmacokinetics
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Recombinant Proteins
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
lenzilumab